Intelligence / Healthtech / New Clinical Trials / Kura Oncology, Inc.
Clinicaltrial registered10 Nov 2026
Kura Oncology, Inc.
10 Nov 2026: Trial registered · Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 10 Nov 2026
- Title
- Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
- Conditions
- Myelodysplastic Syndrome (MDS)/AML, Myeloid Leukemia, Acute
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07929740
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Kura Oncology, Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.